MAP2K7 and neuroblastoma: In conclusion, only NF1 loss but not the expression of oncogenic NRASQ61K seems to trigger loss of feedback-mediated MEK reactivation and leads to increased sensitivity of neuroblastoma cell lines harboring ALK mutations to MEK inhibition.